Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Sold by Sumitomo Mitsui Trust Group Inc.

Sumitomo Mitsui Trust Group Inc. trimmed its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 5.6% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 2,825,361 shares of the company’s stock after selling 167,302 shares during the period. Sumitomo Mitsui Trust Group Inc.’s holdings in Intellia Therapeutics were worth $20,088,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in NTLA. Oppenheimer & Co. Inc. acquired a new stake in Intellia Therapeutics in the 4th quarter valued at about $209,000. Jones Financial Companies Lllp grew its stake in Intellia Therapeutics by 140.9% in the 4th quarter. Jones Financial Companies Lllp now owns 3,898 shares of the company’s stock valued at $45,000 after acquiring an additional 2,280 shares during the last quarter. Aigen Investment Management LP acquired a new stake in Intellia Therapeutics in the 4th quarter valued at about $213,000. Arizona State Retirement System grew its stake in Intellia Therapeutics by 6.1% in the 4th quarter. Arizona State Retirement System now owns 28,006 shares of the company’s stock valued at $327,000 after acquiring an additional 1,615 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in Intellia Therapeutics in the 4th quarter valued at about $4,793,000. 88.77% of the stock is owned by institutional investors and hedge funds.

Intellia Therapeutics Stock Down 0.1%

NTLA stock opened at $10.72 on Friday. The company has a market cap of $1.11 billion, a price-to-earnings ratio of -2.05 and a beta of 2.21. The business has a fifty day simple moving average of $8.73 and a 200-day simple moving average of $9.40. Intellia Therapeutics, Inc. has a 52 week low of $5.90 and a 52 week high of $28.18.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings data on Thursday, May 8th. The company reported ($1.10) EPS for the quarter, topping analysts’ consensus estimates of ($1.26) by $0.16. Intellia Therapeutics had a negative return on equity of 56.06% and a negative net margin of 1,154.10%. The business had revenue of $16.63 million during the quarter, compared to the consensus estimate of $11.39 million. During the same period in the prior year, the firm posted ($1.12) EPS. The business’s revenue for the quarter was down 42.6% on a year-over-year basis. As a group, analysts expect that Intellia Therapeutics, Inc. will post -5.07 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the stock. Guggenheim lowered their price objective on shares of Intellia Therapeutics from $55.00 to $45.00 and set a “buy” rating on the stock in a research note on Monday, May 12th. HC Wainwright restated a “buy” rating and issued a $30.00 target price on shares of Intellia Therapeutics in a report on Monday, June 16th. Chardan Capital restated a “buy” rating and issued a $68.00 target price on shares of Intellia Therapeutics in a report on Friday, May 9th. Citigroup reduced their target price on shares of Intellia Therapeutics from $14.00 to $10.00 and set a “neutral” rating on the stock in a report on Friday, May 9th. Finally, Wolfe Research upgraded shares of Intellia Therapeutics from a “peer perform” rating to an “outperform” rating and set a $21.00 target price on the stock in a report on Monday, April 21st. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Intellia Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $33.37.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.